Cosmo is a pharmaceutical company with a focus on gastrointestinal(GI) diseases and Dermatology. Cosmo’s development pipeline is focused on Bowel Diseases, Colon Infections, and products to increase the detection of cancerous and pre-cancerous lesions during colonoscopy. Cosmo’s proprietary multi-matrix MMX technology allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets, in a delayed and controlled way, with the effect that the active pharmaceutical ingredients can be applied to the full length of the colon. Besides, Cosmo is actively developing a new pipeline of Artificial Intelligence applications in endoscopy, to solve unmet clinical needs across the GI space, toward a more effective standard of care. Cosmo is a publicly traded company listed on the Swiss Stock Exchange (SIX: COPN).
Medac is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business. Established in 1970 in Northern Germany, Medac is specialised in the treatment of urological, oncological, haematological and autoimmune diseases as well as in the development of diagnostic devices. Besides an already established product portfolio, Medac is dedicated to the refinement of existing and the development of new therapeutic products providing patients with leading-edge individualised treatments. In the field of urology, Medac focuses on instillation therapies for non-muscle invasive bladder cancer.
Sparc is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. Sparc has extensive drug development experience in areas of new chemical entities and novel drug delivery systems. Its delivery platform technologies are clinically validated with products approved in several markets.
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business and a skilled team enable it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7-8% of annual revenues in R&D.
Can-Fite BioPharma, an Israeli clinical-stage biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, liver diseases as well as sexual dysfunction. The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. Can-Fite BioPharma was founded in 1994 and is headquartered in Petah Tikva, Israel. It is listed on the Tel Aviv Stock Exchange (TASE: CFBI) and the New York Stock Exchange (NYSE: CANF).
Zydus, a leading Indian Pharmaceutical company, is a fully integrated, global healthcare provider that discovers, develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines. Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously, it dedicates to creating healthier, happier communities across the globe. The group employs nearly 25,000 people worldwide with 1,400 scientists engaged in the R&D department.
